cilnidipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcium channel blockers, nifedipine derivatives	642	132203-70-4

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

FRC-8653
cilnidipine
cinaldipine
cinalong

has excitatory & inhibitory action on the Ca+ channels in the rabbit basilar artery; structure given in first source; RN given is for (+-) isomer

Molecular weight: 492.53
Formula: C27H28N2O7
CLOGP: 5.54
LIPINSKI: 1
HAC: 9
HDO: 1
TPSA: 117
ALOGS: -5.94
ROTB: 12

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Renal impairment	56.48	30.34	27	846	75634	50528617
Hepatic function abnormal	48.59	30.34	19	854	32662	50571589

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral infarction	56.42	28.65	27	1531	24648	29548321
Hyperkinetic heart syndrome	49.31	28.65	8	1550	110	29572859
Hepatic function abnormal	42.07	28.65	26	1532	39233	29533736
Interstitial lung disease	41.95	28.65	30	1528	57688	29515281
Renal impairment	41.00	28.65	34	1524	81299	29491670
Stress cardiomyopathy	37.73	28.65	10	1548	1614	29571355
Cardiac vein perforation	35.31	28.65	5	1553	25	29572944
Echocardiogram abnormal	33.36	28.65	8	1550	863	29572106

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic function abnormal	83.53	28.30	45	2734	64268	64431685
Renal impairment	79.38	28.30	57	2722	134960	64360993
Cerebral infarction	71.45	28.30	35	2744	41009	64454944
Hyperkinetic heart syndrome	50.26	28.30	8	2771	120	64495833
Interstitial lung disease	41.39	28.30	34	2745	97698	64398255
Hyperkalaemia	38.32	28.30	33	2746	101096	64394857
Cardiac vein perforation	36.31	28.30	5	2774	25	64495928
Hyperuricaemia	34.94	28.30	14	2765	10177	64485776
Platelet count decreased	34.16	28.30	39	2740	167672	64328281
Embolic stroke	33.02	28.30	12	2767	6699	64489254
Stress cardiomyopathy	29.27	28.30	12	2767	9245	64486708
Echocardiogram abnormal	29.23	28.30	8	2771	1781	64494172
Nephrogenic anaemia	28.42	28.30	9	2770	3316	64492637

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C08CA14	CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives
MeSH PA	D002121	Calcium Channel Blockers
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
CHEBI has role	CHEBI:35554	cardiovascular agent
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:38215	calcium channel blockers

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.67	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Voltage-gated L-type calcium channel	Ion channel	Q01668 Q13936	CAC1D_HUMAN CAC1C_HUMAN	BLOCKER				SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Voltage-dependent T-type calcium channel subunit alpha-1H	Ion channel	O95180	CAC1H_HUMAN		IC50	4.62		CHEMBL
Voltage-dependent N-type calcium channel subunit alpha-1B	Ion channel	Q00975	CAC1B_HUMAN		IC50	4.58		CHEMBL
Voltage-dependent N-type calcium channel subunit alpha-1B	Ion channel		CAC1B_RAT	BLOCKER	IC50	6.70		IUPHAR

External reference:

ID	Source
D01173	KEGG_DRUG
C0378675	UMLSCUI
CHEBI:31399	CHEBI
CHEMBL452076	ChEMBL_ID
DB09232	DRUGBANK_ID
C065927	MESH_SUPPLEMENTAL_RECORD_UI
7767	IUPHAR_LIGAND_ID
6880	INN_ID
97T5AZ1JIP	UNII
5282138	PUBCHEM_CID
010899	NDDF
1177123004	SNOMEDCT_US
1179035008	SNOMEDCT_US

Pharmaceutical products:

None